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Abstract 
 
A number of drugs developed against cancer-specific molecular targets have been shown to offer 
survival benefits alone or in combination with standard treatments, especially for those cases where 
tumor pathogenesis is dominated by a single molecular abnormality. One example for such a tumor 
type is alveolar rhabdomyosarcoma (aRMS) which is characterized by a specific translocation creating 
the oncogenic PAX3/FKHR transcription factor, believed to be the molecular basis of the disease. 
Recently, we were able to demonstrate that the small molecule inhibitor PKC412 (midostaurin) 
exhibits strong antitumor activity against aRMS by reducing the transcriptional activity of PAX3/FKHR.  
Here, we screened for combination strategies that are superior to PKC412-only treatment and found 
that the combination of PKC412 with histone deacetylase (HDAC) inhibitors like valproic acid (VPA) 
synergistically induced apoptosis resulting in suppressed aRMS tumor growth in vivo. 
We provide evidence that the antitumor effect upon combination treatment is achieved by VPA-
induced reactivation of p21 which is downregulated in aRMS cells via destabilization of the 
transcriptional regulator EGR1 by PAX3/FKHR. Our study highlights a possible mechanism behind the 
increased efficacy and indicates that different arms of PAX3/FKHR oncogenicity can be exploited 
therapeutically by the specific combination of drugs to increase their therapeutic potential.   
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Introduction 
 
The phenomenon of oncogene addiction allows the development of targeted therapies for poor-
outcome malignancies whereby the clinical success of kinase inhibitors such as imatinib demonstrate 
the feasibility of such an approach. However, clinical experience also indicates that the risk of 
outgrowth of therapy-resistant subclones with single agent treatments is rather high and their efficacy 
can be very limited. Hence, and given the vast number of agents in pre-clinical development, one of 
the big challenges ahead will be to define rational combination treatments that show the most 
promising clinical benefit. Such combinations might be directed against one signalling pathway at 
different molecular levels or target complementary pathways to achieve maximal efficacy. 
As a model to explore such possibilities we use the pediatric sarcoma rhabdomyosarcoma (RMS). 
RMS is the most common pediatric soft tissue cancer and accounts for about 5-8% of all malignancies 
in children (Merlino and Helman, 1999). Histopathologically, two main subtypes of RMS, embryonal 
RMS (eRMS) and alveolar RMS (aRMS) can be distinguished. While eRMS has a favourable 
prognosis with survival rates of up to 94 % for the most favourable subgroups, the aRMS histotype is 
associated with poor survival rates of 30 % only as aRMS occurs at unfavourable sites and 
demonstrates a highly malignant phenotype (Meyer and Spunt, 2004). Also within the stratified patient 
cohort of metastatic RMS with two or fewer metastatic sites, non-embryonal histology is associated 
with an unfavourable prognosis while embryonal histology contributes significantly to better prognosis, 
with 21% and 40% of failure-free survival, respectively (Breneman et al., 2003). Dose intensification 
and the use of multiagent chemotherapy offer only very modest survival benefits for children with 
disseminated or recurrent disease and unfavourable RMS histology (Pappo et al., 1999; Smith et al., 
2001). Therefore, new therapeutic strategies are urgently needed for such high-risk patients.  
The majority of aRMS cases is associated with the chromosomal translocation t(2;13) generating the 
PAX3/FKHR fusion protein. This chimeric transcription factor contains the two DNA binding domains 
of PAX3 and the transactivation domain derived from FKHR, also known as FOXO1A. As PAX3/FKHR 
is a stronger transactivator than its wild-type counterpart, it has been suggested that the oncogenic 
potential of the fusion results from dysregulation of PAX3 target genes. Established aRMS tumors are 
dependent on continuous expression of PAX3/FKHR similar to multiple examples of cancers that show 
to be addicted to certain activated oncogenes. Hence, these tumor-specific oncogenic transcription 
factors represent an ideal therapeutic target for the development of novel therapeutic strategies.  
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Along these lines, we recently reported that the kinase inhibitor PKC412 (midostaurin) can influence 
the oncogenic activity of PAX3/FKHR through modulation of specific phosphorylation sites within the 
PAX3 domain (Amstutz et al., 2008). Phosphorylation at these sites was shown to perturb efficient 
DNA-binding. Consequently, treatment of aRMS with PKC412 resulted in potent antitumoral effects 
both in vitro as well as in vivo.  
Apart from this well-investigated oncogenic activity at the level of direct target gene activation, 
PAX3/FKHR also exerts a repressive effect that has been less well characterized. Recently, it has 
been reported that PAX3/FKHR has a protein-destabilization effect (Roeb et al., 2007), as 
PAX3/FKHR was shown to directly interact with the early growth responsive transcription factor EGR1 
thereby targeting EGR1for proteasomal degradation. EGR1 plays important roles in regulating cell 
growth, differentiation and development (Liu et al., 1996) and has been shown to mediate expression 
of p57Kip2 as one of its target genes.  
Here we demonstrate that degradation of EGR1 by PAX3/FKHR leads to the repression of the tumor 
suppressor and cell cycle regulator p21 and thereby identify p21 as a novel gene that is repressed by 
PAX3/FKHR.  
In an attempt to find substances synergistic with PKC412 in their ability to inhibit aRMS cell 
proliferation, we found that reactivation of p21 expression by HDAC inhibitors strongly augments 
PKC412-mediated apoptosis in aRMS cells, in vitro and in vivo. These findings highlight the 
complexity of aRMS tumor pathogenesis created by the translocation positive genotype and provide 
the basis for a evidence-based combination treatment of aRMS with PKC412 and HDAC inhibitors to 
exert a therapeutic benefit by targeting different arms of PAX3/FKHR oncogenicity.  
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RESULTS 
 
Combination of PKC412 with VPA leads to synergistic antitumor activity on aRMS cells in vitro 
through reactivation of p21 expression levels. 
We recently identified PKC412 as a potent antitumorigenic agent for aRMS treatment in vitro and in 
vivo (Amstutz et al., 2008). To further increase treatment efficacy, we performed in vitro combination 
studies with chemotherapeutic agents used in RMS therapy or HDAC inhibitors which have been 
shown to act synergistically with PKC412 against acute myelogenous leukaemia (AML) (Bali et al., 
2004). IC50 values of these agents were determined in aRMS cell lines RH4 and RH30 either as single 
agents or in combination with 50nM PKC412, a concentration which is about 10 times below its IC50 
and thus only has a marginal influence on cell viability by itself. To evaluate synergistic effects, a 
combination index (CI) was calculated which is the IC50 ratio between combined and single treatments 
and which indicates synergism at a value <1. Strong synergistic effects with CI values of 0.48 and 0.61 
were observed in RH4 cells for both HDAC inhibitors, VPA and SAHA, whereas from the 
chemotherapeutic compounds only vincistrine showed weak synergism in combination with PKC412. 
In RH30 cells, all compounds tested showed some synergistic effects with PKC412. Similar to RH4 
cells, the lowest CI value could be detected upon cotreatment with VPA (Figure 1a). These results 
suggest a rationale for combining PKC412 and HDAC inhibitors, especially VPA, and prompted us to 
further investigate this combination for treatment of aRMS. 
To confirm VPA as a combination partner for PKC412, we next determined whether cotreatment with 
clinical applicable concentrations of VPA would sensitize aRMS cells to cell death induced with IC50 
concentrations of PKC412. As expected, single treatment with 0.5µM PKC412 resulted in a strong 
induction of cell death for both aRMS cell lines. By itself, VPA exerted no cytotoxicity following 72h of 
continuous exposure to 1mM. However, cotreatment with 1mM VPA dramatically enhanced PKC412-
induced cell death, indicating synergistic antitumoral activity on aRMS cells (Figure 1b). 
As PKC412 induced cell death is due to caspase-3-dependent apoptosis (Amstutz et al., 2008), we 
tested whether VPA might further enhance apoptosis by an activated caspase-3 assay. This revealed 
an at least 2-fold increase in the number of apoptotic cells in combined treatment compared to 
PKC412 single treatment (Figures 2a and b). RH4 cells showed an increased apoptotic response 
compared to RH30 cells, with values of 50.8% and 42.5% respectively, consistent with the observed 
stronger induction of cell death for these cells.  
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To further confirm these findings we monitored PARP cleavage in cells treated with drugs from 2 to 
16h by Western blot analysis. In both aRMS cell lines time-dependent increase in PARP cleavage was 
more pronounced after combination treatment compared to either single treatment alone (Figure 2c). 
In addition to VPA we observed that also other HDAC inhibitors like sodium butyrate or SAHA (Figures 
1a, b and data not shown) can act in combination with PKC412 to mediate an enhanced reduction of 
aRMS cell viability. Taken together, these results clearly show that HDAC inhibitors synergize with 
PKC412 to enhance apoptosis in aRMS cells. Since different HDAC inhibitors have a similar 
synergistic effect, their mode of action is likely to rely on a class-specific mechanism.  
One very prominent effect observed for a large panel of HDAC inhibitors is induction of p21 (Archer et 
al., 1998; Kim et al., 2001; Sowa et al., 1997; Wilson et al., 2006). Hence, we determined p21 
expression levels upon HDAC inhibitor treatment alone and in combination with PKC412. p21 protein 
levels were significantly upregulated upon HDAC inhibitor treatment irrespective of additional 
treatment with PKC412 (Figure 2d and Supplementary Figure S1a). This is true for both aRMS cell 
lines RH4 and RH30, which demonstrate similar levels of PAX3/FKHR expression (Supplementary 
Figure S1b) and are either deleted in p53 or carry p53 mutations (Barlow et al., 2006), thereby 
excluding a role of p53 in p21 promoter activation.   
These observations suggest that the synergistic antitumoral effects of the combination might result 
from upregulation of the well-established HDAC inhibitor target p21. To verify the functional 
significance of p21 induction for enhanced apoptotic response, we prevented p21 accumulation using 
RNAi and compared the level of apoptosis upon VPA/PKC412 exposure to control siRNA treated cells. 
As shown in Figure 2d  the extent of PARP cleavage upon combination treatment increased to a ratio 
of 0.4 compared to 0.3 observed for PKC412 only treatment . In p21-depleted cells this ratio remained 
unchanged at 0.3 indicating that p21 depletion prevents VPA from enhancing PKC412-induced 
apoptosis (p=0.0133). Collectively, these data suggest that induction of p21 by VPA is an important 
component contributing to enhanced apoptosis upon cotreatment with PKC412.  
 
PAX3/FKHR mediates repression of p21. 
Because a number of oncogenes repress p21 to promote tumorigenesis (as reviewed in (Gartel and 
Radhakrishnan, 2005)), we sought to determine whether also the PAX3/FKHR oncogene exerts a 
suppressive effect on p21 expression. Hence, we silenced endogenous PAX3/FKHR in aRMS cells 
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and measured p21 protein levels. As shown in Figure 3a and Supplementary Figure S2 reduced 
PAX3/FKHR levels led to dramatic increase in p21 protein expression in a panel of aRMS cell lines. 
To further validate PAX3/FKHR as a negative regulator of p21 expression, we examined its effect 
directly on the p21 promoter by luciferase reporter assays. Transfection of 293T cells with a 
PAX3/FKHR vector decreased p21 promoter driven luciferase expression to 26% (Figure 3b).  
As PAX3/FKHR interferes with expression of p21 and aRMS cells undergo apoptosis on silencing of 
PAX3/FKHR by oligonucleotides (Bernasconi et al., 1996) or siRNA (Ebauer et al., 2007), we 
assessed the relevance of p21 induction for this apoptotic response by cotransfecting RH4 cells with 
siRNAs against p21 and PAX3/FKHR. Compared to control or p21 siRNA transfected cells, which only 
show ratios of cleaved to uncleaved PARP of 0.1 and 0.07 respectively, PAX3/FKHR siRNA 
transfected cells demonstrate strongly enhanced PARP cleavage (0.43). Importantly, this apoptotic 
response to PAX3/FKHR silencing was rescued upon codepletion of p21 as indicated by a reduction 
of PARP cleavage ratio to 0.18 (Figure 3c). These results demonstrate that PAX3/FKHR represses 
p21 levels and suggest that upregulation of p21 in response to PAX3/FKHR downregulation is 
necessary for efficient induction of apoptosis.  
 
PAX3/FKHR controls expression of p21 via EGR1  
Because inhibition of DNA-binding of PAX3/FKHR by PKC412 (Amstutz et al., 2008) was not able to 
induce p21 expression (Figure 2d) we reasoned that PAX3/FKHR might regulate p21 gene expression 
at levels other than transcription. Recently, it has been demonstrated that PAX3/FKHR can interact 
with and mediate destabilization of the transcription factor EGR1 ((Roeb et al., 2007) and 
Supplementary Figures S3a and b) which itself can directly modulate gene expression of p21 ((Choi et 
al., 2008; Ragione et al., 2003) and Supplementary Figure S3c)). These findings suggest that 
repression of p21 by PAX3/FKHR might be mediated by degradation of the transcription factor EGR1.  
To address this hypothesis, we first examined the expression levels of p21 and EGR1 in control 
human myoblasts and a series of aRMS tumor cell lines by immunoblot analysis. These experiments 
revealed a significant decrease in both p21 and EGR1 protein expression levels in aRMS cell lines in 
comparison to control myoblasts (Figure 4a).  
Proteasome inhibition by MG132 prevents EGR1 destabilization by exogenous PAX3/FKHR in 293T 
cells ((Roeb et al., 2007) and Supplementary Figure S3b.) Therefore, we treated aRMS cells with 
MG132. This caused a dose-dependent increase both of EGR1 and p21 protein levels (Figure. 4b). As 
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p21 itself is subject to ubiquitination, this increase most likely results from increased p21 protein 
stability rather than elevated transcription levels induced by EGR1. In order to investigate the 
relevance of EGR1-destabilization by PAX3/FKHR on p21 transcription, we performed luciferase 
reporter assays using a p21-promoter deletion construct lacking the distal p53 consensus binding site.  
As shown in Figure 4c in 293T cells, p21 promoter activity increased with the amount of transfected 
EGR1, suggesting that EGR1 can induce p21 transcription independent of p53. Moreover, 
coexpression of PAX3/FKHR inhibits EGR1 activation of the p21 promoter in a dose-dependent 
fashion. Interestingly, this inhibition could be partially rescued by treatment with increasing amounts of 
MG132 (Figure 4d and Supplementary Figure S3b). This suggests that p21 protein levels are 
controlled in aRMS cells via transcriptional activation by EGR1 which itself is destabilized by 
PAX3/FKHR.  
To further validate this hypothesis, we assessed whether silencing of EGR1 influences p21 expression 
levels. As shown in Figure 4a, untreated RH4 cells express only low levels of endogenous EGR1 
protein. Moreover, further depletion by RNAi mediated yet a reduction of p21 expression which was 
proportional to EGR1 knockdown efficiency (Figure 4e and Supplementary Figure S3d). In addition, 
silencing of PAX3/FKHR mediated an increase in EGR1 as well as p21 protein levels. These data are 
consistent with the notion that EGR1 regulates p21 transcription and that upon knockdown of 
PAX3/FKHR, EGR1 is no longer subject to proteasomal degradation and hence able to 
transcriptionally activate p21. 
 
PKC412/VPA combination treatment results in reactivation of p21 expression levels and 
enhanced antitumoral action in vivo. 
To investigate the value of combination therapy in vivo, we used an aRMS xenograft mouse model 
generated by subcutaneous injection of RH4 cells into immunocompromised (nu/nu) mice. As shown 
in Figure 5a, daily administration of VPA (400 mg/kg) or PKC412 (100 mg/kg) alone for a 7-day time 
period was able to reduce tumor growth by about 50%. Interestingly, combination treatment reduced 
tumor growth by a further 3-4 fold compared to either single treatment alone.  
In line with our in vitro results, immunohistochemical analysis of tumor sections revealed that VPA 
treatment alone or in combination with PKC412 led to elevated levels of p21 protein in vivo (Figure 
5b). In addition, analysis of tumors subjected to each single treatment showed that VPA had only a 
minimal effect on proliferation whereas PKC412 treatment caused a 25% reduction in the number of 
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proliferative cells (Figure 5c). Both single treatments also led to a 2-fold increase in the number of 
apoptotic cells compared to placebo treated tumors (Figure 5d). Importantly however, combination 
therapy resulted in both strongest decrease in proliferation (by 40%) and highest number of apoptotic 
cells (72 cells/visual field) compared to placebo treatment (11 cells/visual field) (Figures 5C and D). In 
summary, these results suggest that also in vivo reactivation of p21 contributes to augment PKC412 
mediated antitumorigenic activity and therefore highlight a PKC412/VPA combination treatment as a 
evidence-based novel treatment strategy for aRMS. 
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Discussion 
 
aRMS represents a therapeutic challenge because of its frequent resistance to conventional 
chemotherapy. Especially relapsed aRMS patients have a very poor prognosis (Pappo et al., 1999; 
Raney et al., 2001). Therefore, the development of novel treatment modalities in necessary to improve 
the clinical outcome for aRMS patients. 
Recently, we identified the kinase inhibitor PKC412 to exert a potent antitumor effect in aRMS in vitro 
and in vivo by reducing the transcriptional activity of the PAX3/FKHR oncogene (Amstutz et al., 2008). 
However, to minimize the potential development of resistance and further improve efficacy the use of 
drug combinations is a well-established pharmaceutical principle. Since numerous novel agents are 
now being developed for clinical testing this creates almost limitless possibilities of combination 
regimens. Therefore, development of strategies to identify the most promising combinations will 
become very important. 
Here, we demonstrate that the HDAC inhibitor VPA, a well-established drug used in therapy for 
seizures and bipolar disorders, acts as a potent combination partner for PKC412 to mediate increased 
induction of apoptosis in aRMS cells, both in vitro and in vivo. Interestingly, combinations with 
standard cytotoxic drugs used in RMS treatment showed only minimal synergistic effects. This is in 
contrast to acute myeloid leukaemia (AML) for which PKC412 is currently evaluated in phase II clinical 
trials, as combinations with conventional antileukemic agents demonstrate superior anti-cancer activity 
for FLT3 mutation-positive AML compared to single treatment alone (Furukawa et al., 2007). Only one 
study in AML suggested that HDAC inhibitors could be used effectively in combination with PKC412 
(Bali et al., 2004).  
In vivo, further reduction in tumor growth by the combination was observed after a short treatment 
period of only seven days. It will be interesting to evaluate this combination in respect to other targeted 
drugs that have been suggested as novel drugs for therapy of rhabdomyosarcoma, such as for 
example agents inhibiting the IGF-1R pathway (Cao et al., 2008; Kolb et al., 2008).  
We provide evidence that VPA exerts its synergistic anti-cancerous activity on aRMS cells by 
mediating reactivation of p21 expression levels, again both in vitro and in vivo. Interestingly, this effect 
could also be observed with other HDAC inhibitors and was not restricted to VPA. Epigenetic 
repression of p21 has recently been shown to occur via HDAC4-mediated reduced acetylation of 
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Sp1/Sp3-binding sites at the proximal promoter of p21 in a human glioblastoma model (Mottet et al., 
2009). This effect was shown to be p53-independent which is similar to the results obtained here since 
aRMS cell lines used in this study are either depleted of mutated in p53 (Barlow et al., 2006) and the 
p21 reporter construct did not include p53 binding sites. Hence, transcriptional repression of p21 might 
occur through HDAC4 also in the rhabdomyosarcoma model and the use of more specific HDAC4 
inhibitors might further enhance the specificity of our treatment strategy. 
Since p21 levels in aRMS are usually low (Figures 3 and 4), an important goal was to identify the 
relevant mechanisms of repression. Interestingly, we found that p21 expression is strongly 
upregulated upon silencing of PAX3/FKHR. In addition, efficient induction of apoptotic aRMS cell 
death upon PAX3/FKHR depletion occurs, at least in part, through p21 since its depletion can rescue 
from apoptosis.  Given that PAX3/FKHR can destabilize the transcription factor EGR1 (Roeb et al., 
2007; Roeb et al., 2008) and that EGR1 itself was shown to modulate p21 transcription (Ragione et 
al., 2003), we hypothesized that EGR1 is critically involved in p21 activation upon PAX3/FKHR 
depletion. This conclusion is supported by several lines of evidence: First, EGR1 and p21 protein 
expression levels are reduced in a series of translocation positive aRMS tumor cell lines as compared 
to human myoblasts. Second, enhanced induction of p21 reporter activity upon EGR1 overexpression 
was strongly inhibited by cotransfection with PAX3/FKHR. Third, this inhibition could be prevented by 
treatment with the proteasome inhibitor MG132. Finally, silencing of endogenous PAX3/FKHR induced 
protein expression of both EGR1 as well as its transcriptional target p21. Hence, we identified with 
p21, apart from p57 (Roeb et al., 2007), a second important target gene which is transcriptionally 
modulated by destabilization of EGR1 through PAX3/FKHR thereby also validating this newly 
described role of PAX3/FKHR in aRMS tumor cells (Roeb et al., 2007). These data indicate that aRMS 
tumor cells exert both epigenetic regulatory strategies and destabilization of the transcription factor 
EGR1 as complementing mechanisms to ensure downregulation of p21, indicating a potential tumor 
suppressing function for p21 also in aRMS pathology.  
These data also suggest novel treatment possibilities for aRMS tumors: One rationale might be to 
explore the proteasome as a target of potential therapeutic value. However, as it could be shown that 
PAX3/FKHR rather than EGR1 is ubiquitinated (Roeb et al., 2008), strategies that exploit proteasome 
inhibition might also lead to increased protein levels of transcriptional active PAX3/FKHR in aRMS 
tumor cells. Therefore, we propose combination strategies of PKC412 with HDAC inhibitors such as 
VPA, as this cotreatment results in reactivation of the EGR1 target p21 and in reduction of the 
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transcriptional activity of PAX3/FKHR. Thus, the molecular mechanism of this synergistic combination 
is most likely based on targeting both the transcriptional and protein-degradation activity of the 
PAX3/FKHR oncogene (Figure 6). As both therapeutic agents used for the combination treatment are 
broad spectrum drugs, it is likely that other so far not identified mechanisms might contribute to their 
activity. Nevertheless, the use of HDAC isoform specific inhibitors combined with more specific kinase 
inhibitors (after identification of the signalling pathway responsible for PAX3/FKHR phosphorylation) 
might provide additional specificity to this treatment strategy. Whether this would also translate to 
enhanced clinical benefits, remains to be investigated.  
Altogether, our study provides novel insights into the oncogenic mechanisms of PAX3/FKHR and 
marks the combination of VPA and PKC412 as an evidence-based alternative to standard 
chemotherapy protocols for poorly prognosed aRMS patients.  
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Materials and Methods 
 
Cell lines and pharmacologic inhibitors. Alveolar rhabdomyosarcoma cell lines RH4 and RH28 
were kindly provided by Peter Houghton (St. Jude Children's Hospital, Memphis, TN, USA) and 
RMS13 were obtained from the Ludwig-Maximillans-University (Munich, Germany). RH30 as well as 
293T cells were purchased from the American Type Culture collection (ATCC, LGC Promochem, 
Molsheim Cedex, France). A33 and B6M myoblasts were established in our laboratories (Genini et al., 
1996). SkM1 and SkM2 myoblasts were purchased from Promocell (Allschwil, Switzerland). 
Etoposide, Vincristine, Carboplatin, Natrium Butyrate and VPA were purchased from Sigma (Buchs, 
Switzerland). Daunorubicine (Cerubidine®) was obtained from Sanofi-Aventis (Geneva, Switzerland), 
Topotecan from Glaxo Smith Kline (Münchenbuchsee, Switzerland) and SAHA from Alexis 
Biosciences (Lausen, Switzerland). PKC412 was kindly provided by Novartis (Basel, Switzerland). 
 
In vitro combination studies. IC50 values of drugs alone or in combination with 50nM PKC412 were 
determined by MTT assays (Roche, Basel, Switzerland) according to the manufacturer’s protocol.     
10 000 cells per well of a 96-well plate were treated with increasing concentrations of Daunorubicine 
(0 - 3 µM), Etoposide (0 - 30 µM), Topotecan (0 - 10 µM), Vincristine (0 - 5 nM), Carboplatin (0 - 1 
mM), VPA (0 - 30 mM) or SAHA (0 - 6 µM) in a final volume of 100 µl for 96 hours. For each 
concentration, the percent viable cells compared to control was plotted against the logarithm of drug 
concentrations. IC50 values were then calculated by nonlinear regression curve fitting using GraphPad 
Prism software (GraphPad Software Inc., San Diego, CA, USA).  
 
Trypan Blue Exclusion. The dye (Sigma, Buchs, Switzerland) exclusion test was used to determine 
the number of viable and dead cells present in trypsinized cell suspensions upon inhibitor treatment.  
 
Caspase-3 assay. Activated caspase-3 levels were detected by CaspGLOW Red Active Caspase-3 
staining kit (BioVision, Amsbio, Lugano, Switzerland) according to the manufacturer’s instruction. Cells 
were treated with inhibitors for 48h. Active caspase-3 positive cells were determined by fluorescence 
microscopy. For each treatment, a minimum of 500 cells were counted.  
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Immunoblotting. Proteins were separated using a NuPAGE electrophoresis system (Invitrogen, Basel 
Switzerland). Western blots were probed using primary antibodies against poly(ADP-ribose) 
polymerase (PARP, 1:1000), p53 (1:1000), p21Waf1/Cip1 (12D1, 1:1000, all from Cell Signaling 
Technology, Allschwil, Switzerland), EGR1 (588, sc-110, 1:500,Santa Cruz Biotechnology, Heidelberg, 
Germany), FKHR (C20; 1:500; Santa Cruz Biotechnology, Heidelberg, Germany) and β-actin (A2103; 
1:1000; Sigma, Buchs, Switzerland).  
 
siRNA-mediated silencing. Cells were transfected with either PAX3/FKHR break-point specific 
siRNA (Kikuchi et al., 2008), p21 siRNA, EGR1#1 siRNA or scrambled negative control (AllStars) 
siRNA (all obtained from Qiagen except for EGR1#2 from Ambion) for 48h using N-ter nanoparticle 
transfection reagent (Sigma-Aldrich, Buchs, Switzerland) according to the manufacturer’s instructions. 
For knockdown experiments in combination with PKC412/VPA treatment, cells were incubated with 
siRNA for 40h and subsequently exposed to treatment for additional 8h.  
 
Proteasome inhibition assays. RH4 cells were treated with MG132 (VWR international AG, 
Dietikion, Switzerland) dissolved in DMSO or DMSO alone for 3h. For proteasome inhibition during 
luciferase assay experiments 293T cells were treated with indicated concentrations of MG132 sixteen 
hours before harvesting.  
 
Transactivation assays and plasmids.  The PAX3/FKHR construct together with a reporter plasmid 
containing the luciferase gene downstream of a p21 promoter fragment that spans nt -150 to +39 and 
lacks the p53 binding site (p21-Luc (-150/+38), (Kim and Rossi, 2007)) and a plasmid containing the 
lacZ gene were transfected into 293T cells. For EGR1 destabilization assays 293T cells were in 
addition to these plasmids cotransfected with increasing quantities of EGR1 plasmid. Total DNA mass 
was kept constant by the addition of pcDNA3.1. Where indicated, cells were treated with MG132, 
followed by lysis in reporter lysis buffer (Promega, Wallisellen, Switzerland). β-Galactosidase and 
luciferase activities were determined with the corresponding assay systems (Promega, Wallisellen, 
Switzerland) and luciferase activity values were normalized with the β-galactosidase activity values. 
 
Treatment of aRMS xenograft mice. 107 RH4 cells resuspended in 100 µl of PBS, were 
subcutaneously injected into the right flank of female CD-1 athymic nude mice (nu/nu) (Charles River, 
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Germany). When tumors reached a volume of approximately 125 mm3, mice were treated with 100 
mg/kg/day PKC412, 100 mg/kg/day PKC412 and 400 mg/kg/day VPA, 400 mg/kg/day VPA or 
placebo. Treatment was performed for 7 consecutive days. Tumor size was determined every 3 days 
by measuring two diameters (d1, d2) in right angles using a calliper. Tumor volumes were calculated 
using the formula V = (4/3) π r3 (r  = (d1 +d2)/4). PKC412, formulated in a microemulsion (Novartis, 
Basel, Switzerland), was applied orally according to the guidelines of Novartis (Basel, Switzerland). 
Valproic acid, dissolved in PBS, was administered intraperitoneally. Every treatment group consisted 
of 5 animals. 
 
Immunohistochemistry. For histologic analysis, 3 mice per treatment group were sacrificed at the 
end of the in vivo experiment treatment period (day 25). Tumors were isolated, fixed in 4 % 
paraformaldehyde in PBS and paraffin embedded. Tumor sections were subjected to stainings with 
rabbit-polyclonal p21 antibody using standard histological techniques. TUNEL analysis was performed 
according to the manufacturer's instructions (Roche, Basel, Switzerland). Furthermore, tumor sections 
were stained for the proliferation marker Ki-67 by using a monoclonal rabbit Ki-67 antibody 
(NeoMarkers, Fremont, CA, USA) and the Ventana iView DAB Detection Kit. TUNEL- or Ki-67-positive 
cells were counted in 12 randomly selected visual fields at x100 magnification (634.2 µm x 476.5 µm).  
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Figure legends 
 
Figure 1 Screening for combination partners identifies VPA to mediate increased PKC412 drug 
efficacy. (a) aRMS cell lines were treated with increasing concentrations of chemotherapeutic drugs 
and HDAC inhibitors for 96h either alone or in combination with 50nM PKC412. Cytotoxicity was 
determined by using MTT assays and IC50 values were calculated by nonlinear regression curve 
fitting. Ratios of combined versus non-combined treatments <1.0 correspond to synergistic 
interactions. Columns, mean of three independent experiments performed in triplicate; bars, SD. (b) 
aRMS cell lines were exposed to the indicated concentrations of PKC412 and/or VPA for 24 - 72h and 
cell viability (%) was assessed using trypan blue exclusion. Points, mean of three independent 
experiments; bars, SD. 
 
Figure 2 Cotreatment with VPA enhances apoptotic response to PKC412 in aRMS cells. Apoptotic 
RH4 (a) and RH30 (b) cells were detected as caspase-3-positive cells under fluorescence microscopy 
and indicated as % stained cells (right). Columns, mean of three independent experiments; bars, SD. 
(c) Western blot analysis of PARP cleavage after indicated hours of treatment with 0.5µM PKC412 
(P), 1 mM VPA (V) alone or in combination (P+V) compared to DMSO–treated (D) controls. (d) After 
40h of silencing with p21-targeting or scrambled siRNA, RH4 cells were treated with 0.5µM PKC412 
(P), 1mM VPA (V) alone or in combination (P+V) or DMSO (D) for 8h. Quantification of PARP 
cleavage detected by Western blotting was performed using densitometry and ratios of cleaved to 
uncleaved PARP are indicated (results are representative of three independent experiments). p21 
depletion was verified by Western blotting. 
 
Figure 3 p21 expression is upregulated upon silencing of PAX3/FKHR and contributes to efficient 
induction of apoptosis. (a) RH4 cells were transiently transfected with scrambled (sc) or PAX3/FKHR 
(P3F) specific siRNA and expression of p21 and PAX3/FKHR was determined by Western blot 
analysis. (b) Luciferase reporter assay of 293T cells cotransfected with p21 promoter-reporter plasmid 
and PAX3/FKHR (P3F) expression plasmid or empty vector control. Columns, mean of three 
independent experiments; bars, SD. (c) RH4 cells were transfected with a combination of siRNAs 
targeting PAX3/FKHR and p21 and compared to single or scrambled siRNA treated cells.  
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Concentrations of siRNA applied for each target were 25 nM and total siRNA concentrations were kept 
constant (50 nM) by addition of sc siRNA. PARP cleavage was analysed by Western blotting. Bands 
representing cleaved and uncleaved PARP were quantified by densitometry. Knockdown efficiency 
and effects of silencing were assessed by Western blot analysis of p21 and PAX3/FKHR. 
 
Figure 4 PAX3/FKHR regulates p21 expression via EGR1. (a) Expression levels of p21 and EGR1 
were examined by Western blotting of myoblasts and a series of aRMS cell lines. For statistical 
analysis bands were quantified by densitometry and the resulting expression values for EGR1 and p21 
were compared between myoblasts and aRMS cells, *P< 0.05. (b) Western blot analysis of EGR1 and 
p21 expression in RH4 cells treated with increasing concentrations of MG132. (c) Luciferase reporter 
assay of the p21 promoter-reporter plasmid with increasing quantities of EGR1 and PAX3/FKHR alone 
or (d) in the presence of increasing quantities of MG132. Columns, mean of three independent 
experiments; bars, SD. (e) RH4 cells were transfected with siRNAs targeting either 
EGR1(EGR1#1and#2), PAX3/FKHR or scrambled siRNA. Knockdown efficiencies and effects of 
silencing were assessed by Western blot analysis using antibodies against EGR1, PAX3/FKHR and 
p21. 
 
Figure 5 Combination with VPA augments the antitumoral action of PKC412 and induces p21 in vivo. 
(a) Growth curves of aRMS xenografts in nude mice treated either with the combination of 100 
mg/kg/day PKC412 and 400 mg/kg/day VPA or with the single agents alone. Treatment was 
performed from daily during the first 7 days; n = 5. Bar graph shows the tumor growth of treated 
tumors at day 25. Points, means; bars, SD. (b) Representative immunohistochemical analysis of p21, 
(c) Ki-67 and (d) TUNEL stainings of tumors isolated at the end of the in vivo experiment (day 25) 
from each experimental group. Ki-67- and TUNEL-positive cells were scored under light microscopy at 
x100 fold magnification as shown in this figure ; n = 3. Columns, means; bars, SD. *P < 0.05, **P < 
0.01 and ***P < 0.001 compared with placebo-treated mice; §P < 0.05 and §§P < 0.01 compared with 
VPA-treated mice; ††P < 0.01 compared with PKC412-treated mice. 
 
Figure 6 Schematic representation of the molecular interactions described in this study. Briefly, 
phosphorylation regulates the transcriptional activity of PAX3/FKHR (Amstutz et al., 2008) whereas 
22 
ubiquitination of PAX3/FKHR mediates codegradation of the transcription factor EGR1 (Roeb et al., 
2007) thereby reducing p21 expression levels. Therefore, the combination of VPA and PK412 may 
provide a therapeutic benefit in the treatment of aRMS through the abrogation of different levels of 
PAX3/FKHR oncogenic activity.  
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Supplementary Figure S1  (a) HDAC inhibitors upregulate p21 expression levels in aRMS tumor cells 
irrespective of additional PKC412 treatment. Western blot analysis of p21 expression levels in RH4 
and RH30 tumor cells treated with three different HDAC inhibitors either in the presence or absence of 
PKC412 as indicated. β-Actin was used as a loading control. (b) Western blot analysis of PAX3/FKHR 
expression in both aRMS cell lines, RH30 and RH4. 
 
Supplementary Figure S2  p21 protein levels are upregulated upon silencing of PAX3/FKHR in a 
panel of additional aRMS cell lines. aRMS cell lines RH13, RH41 and RH28 were transiently 
transfected with scrambled (sc) or PAX3/FKHR (P3F) breakpoint-specific siRNA for 48 h. PAX3/FKHR 
fusion status of all cell lines and successful knockdown were demonstrated by Western blot analysis of 
PAX3/FKHR. Upregulation of p21 protein levels upon PAX3/FKHR knock-down in all aRMS cell lines 
tested supports the importance of p21 downregulation for PAX3/FKHR oncogenicity. 
 
Supplementary Figure S3  PAX3/FKHR not only interacts with EGR1 but also mediates its 
degradation thereby controlling p21 expression levels. (a) Co-immunoprecipitation analysis of 
endogenous EGR1 and PAX3/FKHR from RH4 cells in the presence or absence of increasing 
amounts of MG132. (b) Western blot analysis of EGR1 upon co-transfection of same amounts of 
EGR1 and increasing amounts of PAX3/FKHR expression plasmids. In the absence of MG132 co-
transfection of increasing amounts of PAX3/FKHR reduce EGR1 protein levels in a dose-dependent 
manner which can be partially rescued by the proteasome inhibitor MG132; these data complement 
the results shown in Figure 4c and d, respectively. (c) Binding of EGR1 to the either the endogenous 
p21 promoter (control sample, c) as well as to p21 promoter region of the p21 (-150/+39) construct as 
detected by chromatin immunoprecipitation (ChIP). Protein/DNA complexes were immunoprecipitated 
with EGR1 antibody or unspecific mouse IgG. The figure shows PCR amplicons of a p21 promoter 
fragment of unprecipitated (input) or precipitated DNA. GAPDH amplification of unprecipitated material 
was used to control the amount of input material. (d) Quantification of the knockdown efficiency of two 
different siRNAs targeting EGR1 by qRT–PCR analysis. Relative percentage of EGR1 mRNA 
compared to scRNA-treated cells (100%) are shown. As seen in Figure 4e the increasing EGR1 
knockdown efficiency also persists on protein levels and likewise results in a graded reduction of p21 
protein levels.  
 
Supplementary Materials and Methods 
 
Real-time PCR. Quantitative reverse transcription-PCR (qRT-PCR) was performed under universal 
cycling variables on an ABI 7900HT instrument using commercially available target probes and Mastermix 
(all from Applied Biosystems, Rotkreuz, Switzerland). Detection of EGR1 was achieved using a specific 
Taqman Gene Expression Assay (Hs00152928_m1). Cycle threshold (CT) values were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Relative expression levels of the target gene upon 
siRNA mediated knockdown were calculated using the CT method. 
 
Chromatin immunoprecipitation (ChIP) assay. ChIP was performed using a commercially available 
ChIP-IT enzymatic kit (Active Motif, Rixensart, Belgium) according to manufacturer’s instructions. 293T 
cells were co-transfected with either empty vector (pGl4.17, Promega, Wallisellen, Switzerland)  or 
pGl4.17 vector containing the p21 promoter fragment that spans nt -150 to +39 (29). DNA-bound protein 
was immunoprecipitated using an anti-EGR1 (Santa-Cruz Biotechnology, Heidelberg, Germany) antibody 
or mouse IgG (Active Motif, Rixensart, Belgium) as negative control. For quantification of co-precipitated 
DNA, samples were than subjected to amplification by employing primers (For: 5’-
AGCTGGCTCGGCGCTGGGCA-3’; and Rev:  5’- GCGGCCCTGATATACAACC-3’) which amplified the 
promoter region (130 bp) of p21. Amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
form the unprecipitated chromatin was used to control the amount of input material. 
 
Co-immunoprecipitation (Co-IP). Co-immunoprecipitation of endogenously expressed proteins was 
performed using RH4 cells either incubated with DMSO or incubated with the indicated amount of MG132 
for 2 hours. Cells were harvested in 1%NP40 lysis buffer. Extracts were incubated overnight with 2.5 µg of 
anti-FKHR (Santa Cruz Biotechnology, Heidelberg, Germany) antibody in the presence of Protein G beads 
using a Protein G Immunoprecipitation kit (Sigma-Aldrich, Buchs, Switzerland) and resulting complexes 
were washed, denatured and eluted according to the manufacturer’s instruction. 
 
EGR1-PAX3/FKHR- Co-Transfection Assay. 293T cells were co-transfected with a constant amount of 
EGR1 plasmid together with increasing amounts of PAX3/FKHR plasmid. Total DNA mass was kept 
constant by the addition of pcDNA3.1. Before harvesting, cells were either incubated with DMSO or 5µM 
MG132 dissolved in DMSO for 16 hours and the obtained extracts were subjected to western blot 
analysis.  
 
 
 
 
 
